NEXGEL (NXGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 May, 2026Executive summary
The annual meeting is scheduled for July 10, 2026, with seven key proposals for shareholder action, including director elections, approval of significant stock issuances, reincorporation, capital structure changes, executive compensation, and auditor ratification.
Shareholders can vote in person, by mail, phone, or online, and the board recommends voting in favor of all proposals.
Proxy materials, including the annual report and proxy statement, are available online and by mail.
Voting matters and shareholder proposals
Seven proposals: election of seven directors, approval of stock issuance exceeding 19.99% of outstanding shares, reincorporation from Delaware to Nevada, increase in authorized shares, discretionary reverse stock split, advisory vote on executive compensation, and auditor ratification.
Proposals 4 and 5 serve as Delaware-law fallbacks if reincorporation is not approved.
Board unanimously recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 annual meeting per SEC rules and company bylaws.
Board of directors and corporate governance
Seven director nominees, including experienced professionals in finance, biotech, and business leadership.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.
Board leadership is separated between the Chairperson and CEO roles.
Code of Business Conduct and Ethics, insider trading, and hedging policies are in place.
Latest events from NEXGEL
- Vote sought on share increase, reverse split, and adjournment to support capital flexibility and compliance.NXGL
Proxy filing - Registering 15.25M shares for resale, company faces dilution and going concern risks.NXGL
Registration filing - Q2 2026 revenue up 27.8% to $3.7M, but net loss widened and integration challenges persist.NXGL
Q2 2026 - Vote sought on share increase, reverse split, and adjournment to support capital flexibility and Nasdaq compliance.NXGL
Proxy filing - Surgeon-focused platform leverages strategic assets and partnerships to drive innovation and growth.NXGL
Investor presentation - Expanded regenerative medicine portfolio and direct sales force set stage for rapid growth.NXGL
Planet MicroCap Las Vegas 2026 - Shareholders will vote on director elections, share issuances, reincorporation, and key governance changes.NXGL
Proxy filing - Record Q2 revenue of $1.44M, with strong outlook driven by branded and Silly George growth.NXGL
Q2 2024 - Q1 2025 revenue up 121% to $2.81M, gross margin at 42.4%, and net loss narrowed.NXGL
Q1 2025